Aprea Therapeutics Inc (Aprea Therapeutics Inc (APRE)) is higher by Thursday morning, with the stock climbing 8.47% in pre-market trading to 8.84.
APRE's short-term technical score of 2 indicates that the stock has traded less bullishly over the last month than 98% of stocks on the market. In the Biotechnology industry, which ranks 75 out of 146 industries, Aprea Therapeutics Inc ranks higher than 2% of stocks.
Aprea Therapeutics Inc has risen 55.53% over the past month, closing at $5.21 on January 14. During this period of time, the stock fell as low as $5.15 and as high as $8.30. APRE has an average analyst recommendation of Buy. The company has an average price target of $13.00.
Aprea Therapeutics Inc has a Long-Term Technical rank of 0. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 100% of the market scoring higher. In the Biotechnology industry which is number 55 by this metric, APRE ranks better than 0% of stocks.
Important Dates for Investors in APRE:
-Aprea Therapeutics Inc is set to release earnings on 3/25/2021. During their last earnings release the company posted EPS of $-5.70. -We do not have a set dividend date for Aprea Therapeutics Inc at this time. Click Here to get the full Stock Score Report on Aprea Therapeutics Inc (APRE) Stock.